Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization predicts that the proportion of the global population over 60 will nearly double from 12% in 2015 to 22% by 2050. The Population Reference Bureau projects that the number of Americans aged 65 and older will increase from 58 million in 2022 to 82 million by 2050. This aging population is driving up demand for healthcare, with US healthcare spending forecast to reach $6 trillion in 2026 from $5.7 trillion in 2025.

While this trend represents a burgeoning market for medical products firms, legal challenges can undermine the advantages of favorable market conditions. Consequently, Johnson & Johnson's proposed settlement of longstanding talc lawsuits is of considerable interest to investors. Johnson & Johnson (NYSE:JNJ) has committed to paying $5.5 billion to settle allegations that its talc-based products caused ovarian cancer.

The settlement encompasses nearly 80,000 outstanding claims. For over a decade, the company has attempted to resolve these lawsuits but encountered obstacles. Recently, however, the situation shifted in the company's favor after a federal judge raised doubts about some crucial expert testimonies connecting talc to individual cancer cases and dismissed one plaintiff's law firm.

Upon approval, the settlement could alleviate the legal uncertainty that has plagued Johnson's shares and management focus for years. Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are prominent pharmaceutical industry leaders, but they offer distinct investment profiles. Johnson has a more diversified business that extends beyond pharmaceutical products to include medical devices and surgical technology.

AbbVie's focus is primarily on branded medicines, particularly in areas like immunology and oncology therapy. Valuation-wise, Johnson trades at a trailing price-to-earnings (P/E) ratio of approximately 30x, while AbbVie's P/E ratio is around 70x. Johnson also boasts a dividend yield of 2.05%, whereas AbbVie offers a higher yield of 2.78%.

A majority of hedge funds held Johnson & Johnson (NYSE:JNJ) shares at the end of Q1 2026, with the number of funds owning the stock rising from 104 to 113. Notable funds such as Fisher Asset Management and Adage Capital Management increased their positions by 5% and 12%, respectively. Conversely, AbbVie's hedge fund holdings grew to 87 funds in Q1, up from 84 in the previous quarter.

In terms of short interest, both stocks have minimal bearish bets. Johnson's short interest was 1.14% as of July 15, equivalent to 27.4 million shares with 3.7 days to cover. AbbVie's short interest was 1.28%, corresponding to 22.6 million shares with 3.5 days to cover. Once finalized, the settlement would enable investors to concentrate more on Johnson's robust fundamentals instead of legal battles and reduce noise around the stock, allowing for greater attention to be paid to Johnson's long track record of returning capital to shareholders.

However, several steps need to be taken before Johnson can conclude the talc issue. For example, the settlement requires the approval of 95% of eligible claimants to be effective. Past settlement plans have not been successful. Despite these challenges, Johnson offers exposure to a more diversified business compared to AbbVie. Additionally, Johnson enjoys higher hedge fund interest, and the resolution of the long-running talc legal dispute could enhance investor sentiment around the stock.

While acknowledging the potential of JNJ as an investment, the author believes certain AI stocks offer greater upside potential and lower downside risk. If seeking an undervalued AI stock that could also benefit significantly from Trump-era tariffs and the onshoring trend, the author recommends a free report on the best short-term AI stock.